Work

Oral icotrokinra for plaque psoriasis in adults and adolescents

Year: 2025

Type: article

Abstract: Oral icotrokinra, a selective interleukin-23 receptor antagonist, is an emerging treatment for moderate-to-severe plaque psoriasis in adults and adolescents. Clinical trials show it significantly reduces Psoriasis Area and Severity Index (PASI) scores and provides symptom relief. It works well in patients who have not used systemic therapies before or have widespread disease. Unlike injectable treatments, icotrokinra is taken orally, making it more convenient and potentially improving adherence. It has shown an effective safety profile, with mostly mild side effects like stomach discomfort and no serious adverse events. As interest in this therapy grows, it may become an important option in psoriasis care, helping to improve quality of life and reduce the long-term burden of this chronic skin condition.

Source: Annals of Medicine and Surgery

DOI: 10.1097/ms9.0000000000004427

Authors: Erum Habib, Ursula Abu Nahla, Muhammad Haris, Muhammad Nabeel Saddique

Institutions: Dow University of Health Sciences, Hebron University, King Edward Medical University

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,850